Potential use of antiviral agents in polio eradication

Emerging Infectious Diseases

Volumn 14, Issue 4, 2008, Pages 545-551

  De Palma, Armando M ^a   Pürstinger, Gerhard ^b   Wimmer, Eva ^b   Patick, Amy K ^c   Andries, Koen ^d   Rombaut, Bart ^e   De Clercq, Erik ^a   Neyts, Johan ^a,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ALPHA HYDROXYBENZYL) BENZIMIDAZOLE; 2' C METHYLADENOSINE; 2' C METHYLCYTIDINE; 4' AZIDOCYTIDINE; ANTIVIRUS AGENT; COMPOUND 1; ENVIROXIME; MRL 1237; NUCLEOSIDE DERIVATIVE; PIRODAVIR; PLECONARIL; POLIOMYELITIS VACCINE; R 78206; RIBAVIRIN; RUPINTRIVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; DRUG USE; ENDEMIC DISEASE; HUMAN; HUMAN CELL; PICORNAVIRUS; POLIOMYELITIS; VACCINATION; VIRUS REPLICATION;

EID: 42049112379     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1404.070439     Document Type: Article

References (39)

1. Griffiths E, Wood D, Barreto L. Polio vaccine: the first 50 years and beyond. Biologicals. 2006;34:73-4.
2. Kimman TG, Boot H. The polio eradication effort has been a great success - let's finish it and replace it with something even better. Lancet Infect Dis. 2006;6:675-8.
3. Arita I, Nakane M, Fenner F. Public health. Is polio eradication realistic? Science. 2006;312:852-4.
4. Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol. 2004;2:473-82.
5. Aylward RB, Sutter RW, Heymann DL. Policy. OPV cessation - the final step to a "polio-free" world. Science. 2005;310:625-6.
6. Couzin J. Report concludes polio drugs are needed - after disease is eradicated. Science. 2006;311:1539.
7. MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O'Leary P, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363:1509-13.
8. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev. In press.
9. De Palma AM, Heggermont W, Leyssen P, Purstinger G, Wimmer E, De Clercq K, et al. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[ 3,4-α] benzimidazoles. Biochem Biophys Res Commun. 2007;353:628-32.
10. McKinlay MA, Pevear DC, Rossmann MG. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol. 1992;46:635-54.
11. Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003;23:339-48.
12. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother. 1995;39:290-4.
13. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001;32:228-35.
14. Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodefi cient patient with poliomyelitis. J Gen Virol. 2003;84:1215-21.
15. Andries K, Rombaut B, Dewindt B, Boeye A. Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound. J Virol. 1994;68:3397-400.
16. Witherell G. AG-7088 Pfizer. Curr Opin Investig Drugs. 2000;1:297-302.
17. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43:2444-50.
18. Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391-6.
19. DeLong DC, Reed SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 1980;141:87-91.
20. Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189-97.
21. Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother. 1988;32:890-5.
22. Higgins PG, Barrow GI, al Nakib W, Tyrrell DA, DeLong DC, Lenox-Smith I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res. 1988;10:141-9.
23. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985;27:102-6.
24. Phillpotts RJ, Jones RW, DeLong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;1:1342-4.
25. Victor F, Loncharich R, Tang J, Spitzer WA. Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality. J Med Chem. 1997;40:3478-83.
26. Victor F, Brown TJ, Campanale K, Heinz BA, Shipley LA, Su KS, et al. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem. 1997;40:1511-8.
27. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350-9.
28. Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 2006;71:379-90.
29. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem. 2003;278:11979-84.
30. Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2′-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 2007;73:161-8.
31. Hadaschik D, Klein M, Zimmermann H, Eggers HJ, Nelsen-Salz B. Dependence of echovirus 9 on the enterovirus RNA replication inhibitor 2-(alpha- hydroxybenzyl)-benzimidazole maps to nonstructural protein 2C. J Virol. 1999;73:10536-9.
32. Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, et al. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol. 2000;74:4146-54.
33. Powers RD, Gwaltney JM Jr, Hayden FG. Activity of 2-(3,4-dichlorophenoxy) -5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother. 1982;22:639-42.
34. Reed SE, Meunch H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493-7.
35. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49:2267-75.
36. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, et al. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004;48:1766-72.
37. Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, et al. Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett. 2007;17:2570-6.
38. Vignuzzi M, Stone JK, Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005;107:173-81.
39. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11-12 October 2006, Part II. Wkly Epidemiol Rec. 2006;81:465-8.